These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2615292)

  • 1. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder.
    Christomanou H; Chabás A; Pámpols T; Guardiola A
    Klin Wochenschr; 1989 Oct; 67(19):999-1003. PubMed ID: 2615292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaucher's disease.
    Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
    J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.
    Aerts JM; Donker-Koopman WE; Brul S; Van Weely S; Sa Miranda MC; Barranger JA; Tager JM; Schram AW
    Biochem J; 1990 Jul; 269(1):93-100. PubMed ID: 2198026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease.
    Kitatani K; Wada M; Perry D; Usui T; Sun Y; Obeid LM; Yaegashi N; Grabowski GA; Hannun YA
    PLoS One; 2015; 10(8):e0136633. PubMed ID: 26312487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaucher's disease in the presence of normal glucocerebrosidase activity.
    Schofield DE; Scott CR; Lage JM; Farrell DF
    Hum Pathol; 1992 May; 23(5):588-92. PubMed ID: 1568755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gaucher's disease--ocular manifestation and treatment].
    Filipek E; Koraszewska-Matuszewska B
    Klin Oczna; 2006; 108(7-9):357-60. PubMed ID: 17290842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher's disease.
    Basu A; Prence E; Garrett K; Glew RH; Ellingson JS
    Arch Biochem Biophys; 1985 Nov; 243(1):28-34. PubMed ID: 3933429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sucrose gradient analysis of phospholipid-activated beta-glucosidase in type 1 and type 2 Gaucher's disease.
    Garrett KO; Prence EM; Glew RH
    Arch Biochem Biophys; 1985 Apr; 238(1):344-52. PubMed ID: 3920967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kinetic study of the effects of galactocerebroside 3-sulphate on human spleen glucocerebrosidase. Evidence for two activator-binding sites.
    Prence EM; Garrett KO; Glew RH
    Biochem J; 1986 Aug; 237(3):655-62. PubMed ID: 3800908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic neuronopathic type of Gaucher's disease with progressive myoclonic epilepsy in the absence of visceromegaly and bone involvement.
    Botross NP; Riad AA; Viswanathan S; Nordin RB; Lock HN
    Scott Med J; 2014 May; 59(2):e1-6. PubMed ID: 24671628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell lymphoma and myeloma in murine Gaucher's disease.
    Pavlova EV; Wang SZ; Archer J; Dekker N; Aerts JM; Karlsson S; Cox TM
    J Pathol; 2013 Sep; 231(1):88-97. PubMed ID: 23775597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant.
    Pàmpols T; Pineda M; Girós ML; Ferrer I; Cusi V; Chabás A; Sanmarti FX; Vanier MT; Christomanou H
    Acta Neuropathol; 1999 Jan; 97(1):91-7. PubMed ID: 9930900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunoelectron microscopic study of glucocerebrosidase in type 1 Gaucher's disease spleen.
    Willemsen R; van Dongen JM; Aerts JM; Schram AW; Tager JM; Goudsmit R; Reuser AJ
    Ultrastruct Pathol; 1988; 12(5):471-8. PubMed ID: 3194992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.
    Vitner EB; Farfel-Becker T; Eilam R; Biton I; Futerman AH
    Brain; 2012 Jun; 135(Pt 6):1724-35. PubMed ID: 22566609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I Gaucher's disease with homozygous R463C mutation without neurological involvement.
    Bolaman Z; Kadikoylu G; Levi E; Barutca S; Temucin K
    Haematologia (Budap); 2002; 32(4):487-93. PubMed ID: 12803123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R; Goa KL
    Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Gba2 on neuronopathic Gaucher's disease and α-synuclein accumulation in medaka (Oryzias latipes).
    Nakanishi E; Uemura N; Akiyama H; Kinoshita M; Masanori S; Taruno Y; Yamakado H; Matsuzawa SI; Takeda S; Hirabayashi Y; Takahashi R
    Mol Brain; 2021 May; 14(1):80. PubMed ID: 33971917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant.
    Christomanou H; Aignesberger A; Linke RP
    Biol Chem Hoppe Seyler; 1986 Sep; 367(9):879-90. PubMed ID: 3024666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of lysosomal hydrolases that are elevated in Gaucher's disease.
    Moffitt KD; Chambers JP; Diven WF; Glew RH; Wenger DA; Farrell DF
    Arch Biochem Biophys; 1978 Sep; 190(1):247-60. PubMed ID: 101149
    [No Abstract]   [Full Text] [Related]  

  • 20. Imprint cytology of Gaucher's disease presenting as a splenic mass. A case report with molecular approaches.
    Kobayashi TK; Tamagaki T; Yoneyama C; Watanabe S; Sugihara H; Ida H
    Acta Cytol; 1998; 42(2):419-24. PubMed ID: 9568149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.